The risk of lean mass loss on GLP-1 therapy is real, documented, and consequential. But it is not inevitable. Patients who implement evidence-based muscle preservation strategies consistently achieve better body composition outcomes — more fat lost, less muscle lost — than those who treat GLP-1 therapy as a passive intervention.
The Protein Priority
The most critical single intervention for muscle preservation on GLP-1 therapy is adequate protein intake. The challenge is that GLP-1-induced appetite suppression reduces total food intake, and protein often falls disproportionately — especially in patients who historically ate high-carbohydrate diets and are now eating significantly less overall.
Clinical data supports a protein target of 1.6–2.2g per kg of ideal body weight daily. For a 160-lb patient, this is approximately 115–160g of protein per day — a target that requires intentional effort when total caloric intake is reduced. Practical approaches include prioritizing protein at every meal before consuming other macronutrients, using protein supplements (whey, casein, or plant-based) to hit targets, and tracking intake during the titration phase when appetite suppression is most significant.
Resistance Training: Non-Negotiable
Resistance training is the most evidence-based intervention for preserving lean mass during caloric restriction. Mechanistically, the muscle protein synthesis stimulation from resistance training directly counteracts the muscle-wasting effects of caloric deficit and creates a specific signal to maintain muscle tissue even when energy balance is negative.
Recommendation: 3–4 sessions per week of progressive resistance training, prioritizing compound movements (squats, deadlifts, rows, presses) that recruit large muscle groups. Intensity should be sufficient to produce meaningful mechanical stress — light resistance at high volume does not produce the same muscle-preservation signal as moderate-to-heavy resistance at lower volume.
Hormonal Optimization
Testosterone is the most powerful endogenous anabolic hormone in both men and women. Optimizing testosterone during GLP-1 therapy directly improves the lean mass:fat mass ratio of weight lost, and in many patients eliminates the lean mass loss that would otherwise occur. This is not optional for patients with documented testosterone deficiency — it is the standard of care for maximizing the clinical value of GLP-1 therapy.
Monitoring Body Composition
Scale weight alone is an inadequate metric for GLP-1 therapy. Patients who lose significant muscle may show excellent scale weight results while achieving poor body composition outcomes. DEXA scan (dual-energy X-ray absorptiometry) is the gold standard for body composition assessment and should be obtained at baseline and at 6-month intervals in patients on long-term GLP-1 therapy. Bioelectrical impedance scales offer a practical (if less accurate) alternative for more frequent monitoring.